ERBB2 and breast carcinoma: Interestingly, recent genomic analyses have shown that the chromosomal amplification sites tend to differ among the molecular breast cancer subtypes as for instance: 17q12 in HER2-overexpressing tumors, 20q13 in luminal-B tumors, 11q13 in both luminal A and B tumors, or 13q34 in basal-like tumors [5,11,14-16].